SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maulcoin

Maulcoin is capturing attention as a community-driven meme project that is consistently trending on social platforms without an official chart, fueling intense community speculation about an upcoming breakout. Holders are actively discussing milestone targets for market capitalization and expressing strong commitment to the project's long-term growth and cultural branding.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is trending as investors digest strong topline results from its Phase 3 RASolute 302 clinical trial, triggering significant price appreciation and active discussion regarding the company's future as a potential buyout target. Community sentiment remains highly bullish, with many highlighting the stock's robust cash position and the transformative potential of its daraxonrasib treatment for pancreatic cancer.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs is trending due to the resignation of its top lawyer amid revelations of ongoing ties to Jeffrey Epstein, triggering a sharp decline in share price. Investors are also closely monitoring the bank's exposure to volatile credit markets and broader concerns regarding institutional stability during a period of geopolitical uncertainty.

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

Aeluma is trending as investors react to the company securing over $4 million in government contracts for quantum materials and lasers, sparking a debate between those betting on long-term technological validation and those skeptical of the company's path to high-volume commercialization. Community discourse is heavily focused on the stock's low float and short interest, fueling speculation of potential volatility and high-reward upside as the company aims to scale its semiconductor integration platform for AI and defense applications.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The VanEck Semiconductor ETF is experiencing intense volatility and heightened scrutiny as traders debate whether current valuation levels represent a sustainable AI-driven growth cycle or an overheated bubble. The community is actively tracking a sharp divergence between high-flying hardware momentum and a struggling software sector, while aggressive options activity and short-dated put sweeps suggest that institutional players are bracing for significant downside risks.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing intense market volatility driven by a massive short squeeze that has triggered a cascade of liquidations for traders betting against the token. The community is actively debating the project's rapid valuation growth and its potential as a decentralized music entertainment protocol, with many highlighting recent exchange listings and upcoming event roadmap milestones as catalysts for continued momentum.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently trading in a volatile spotlight following a combination of a high-profile endorsement from Donald Trump and intense short-selling pressure from investors like Michael Burry. The community remains deeply divided, with bulls pointing to the company's critical role in military AI and defense contracts, while bears raise significant concerns regarding its current valuation and rising competition from alternative AI models.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Ideaya Biosciences is surging following positive Phase 2/3 trial results for its metastatic uveal melanoma treatment, which significantly improved progression-free survival compared to standard therapies. Investors and the community are actively debating the potential for an accelerated FDA filing, while also closely watching for future pipeline updates and high institutional interest.

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Spyre Therapeutics Inc.

Aeglea BioTherapeutics Inc

Spyre Therapeutics is seeing significant investor interest following positive clinical data for its SPY001 program, with the community actively discussing the company's multi-pathway platform approach and its potential to disrupt the IBD market. While some investors are focused on the long-term potential of its upcoming pipeline milestones, others remain cautious regarding the risks typically associated with clinical-stage biotechnology companies.

ProShares Trust - ProShares K-1 Free Crude Oil ETF

ProShares K-1 Free Crude Oil Strategy ETF

ProShares K-1 Free Crude Oil Strategy ETF is attracting attention as the crude market grapples with a significant supply glut and shifting geopolitical dynamics, including potential ceasefire developments and increased global production. Community sentiment is deeply divided, with some investors betting on a continued crash due to record output and rising inventory levels, while others monitor the impact of SPR releases and ongoing supply chain adjustments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

State of Alaska Department of Revenue Cuts Position in Gilead Sciences, Inc. $GILD

State of Alaska Department of Revenue decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.4% during the fourth quarter, according to the company in its most recent...

Greenup Street Wealth Management LLC Purchases Shares of 19,408 Gilead Sciences, Inc. $GILD

Greenup Street Wealth Management LLC bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the...

Sumitomo Mitsui Trust Group Inc. Has $401.25 Million Stock Position in Gilead Sciences, Inc. $GILD

Sumitomo Mitsui Trust Group Inc. lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,269,117 shares of the biopha...

Robeco Institutional Asset Management B.V. Sells 108,349 Shares of Gilead Sciences, Inc. $GILD

Robeco Institutional Asset Management B.V. reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 2.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,693,602 shares...

Massachusetts Financial Services Co. MA Grows Holdings in Gilead Sciences, Inc. $GILD

Massachusetts Financial Services Co. MA increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3,763.8% during the 4th quarter, according to the company in its most...

Pharmaceutical Stocks To Research - April 11th

Eli Lilly and Company, Abbott Laboratories, AbbVie, Pfizer, and Gilead Sciences are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks...

Ritholtz Wealth Management Acquires 7,865 Shares of Gilead Sciences, Inc. $GILD

Ritholtz Wealth Management raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 135,318 shares of the biopharmaceutical company's stock after buy...

KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200

Kymera Therapeutics secures $45M as Gilead licenses KT-200, advancing a novel CDK2 degrader with potential in breast cancer and solid tumors.

Gilead Sciences (NASDAQ:GILD) Price Target Raised to $175.00

Morgan Stanley increased their price objective on Gilead Sciences from $171.00 to $175.00 and gave the company an "overweight" rating in a report on Friday...

<ul class="summary-bullets"><li>The firm said MGNX is uniquely positioned in the emerging Antibody-Drug Conjugate therapy space.</li><li>B. Riley said Gilead’s $5 billion acquisition of Tubulus earlier this week prompted it to develop its own valuation models for ADC firms.</li><li>On Wednesday, MGNX said the U.S. FDA has lifted the partial clinical hold on its Phase 2 trial of a drug to treat cancer.</li></ul>Shares of MacroGenics (MGNX) surged around 10% on Friday, with the stock hitting its highest levels since November 2024. This comes after a bullish analyst call highlighted significant upside potential, with the firm projecting gains of up to 140% from current levels.On Friday, B. Riley upgraded MacroGenics to ’Buy’ from ‘Neutral’ with a $9 price target, according to The Fly.<h2 class="st-heading-2">B. Riley Upgrades Stock After Gilead Tubulus Deal</h2>The brokerage said that after Gilead Sciences’ (GILD) $5 billion deal to acquire Tubulus earlier this week, it developed its own valuation model for next-generation Antibody-Drug Conjugate (ADC) companies and believes MGNX is uniquely positioned in the emerging “ADAM9 TOPO1i ADC space.”ADC is a cancer treatment that combines targeted therapy and chemotherapy.On Tuesday, Gilead Sciences (GILD) <a href="https://stocktwits.com/news-articles/markets/equity/gilead-tubulis-5b-deal-gives-stro-stock-a-boost-here-why/cZJBRoxRIqc">entered</a> into a definitive agreement to acquire Tubulis GmbH, a German clinical-stage biotechnology company. Gilead will pay $3.15 billion upfront, and up to $1.85 billion in additional milestone payments.The deal strengthens Gilead’s ADC pipeline by adding Tubulis’ assets, including TUB-040, a drug in development for ovarian and non-small cell lung cancers.<h2 class="st-heading-2">FDA Lifts Partial Clinical Hold On Ovarian Cancer Trial</h2>On Wednesday, MGNX said the U.S. FDA had lifted the partial clinical hold on its Phase 2 LINNET study of Lorigerlimab, a cancer drug. The trial is testing the drug in patients with certain advanced ovarian and gynecologic cancers who have already received prior treatments.So far, 41 patients have been treated in the study, with over 300 patients dosed across earlier trials.Existing patients were allowed to continue treatment during the hold, and the study will now resume enrolling new patients under an updated protocol with added safety measures.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/MGNX">MGNX</a> on Stocktwits flipped to ‘bullish’ from ‘bearish’, amid high message volumes.One user said the stock’s valuation was “too low.”<stembedurl>https://stocktwits.com/perchedcats/message/649223850</stembedurl>Year-to-date, the stock has surged around 133%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Last week, Baird maintained AYI’s ‘neutral’ rating but cut price target to $320 from $375. (Representative image: Getty Images)

MGNX Stock Hits 16-Month High, But This Analyst Sees Another 140% Potential Upside

B. Riley upgraded MacroGenics to ’Buy’ from ‘Neutral’ with a $9 price target, according to The Fly.

Equity

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

GILD
Gilead Sciences, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GILD News

GILDGilead Sciences, Inc.